cisplatin,gemcitabine,nivolumab
bms
['gu ', 'mibc', 'nivolumab', 'cisplatin', 'hcrn,gu,16-257', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'nivo', 'bladder']
ph2 hcrn gu 16-257 trial presentation by prof. : bladder-sparing potential from the neoadjuvant nivo/cis-based cht combo in mibc. n=76; 79% ; ct3-t4: 44% ccr rate: 43% tmb&gt;10 associated with ypt0 or 2y bladder-intact mfs #gu23 
MD, MSc, Medical Oncologist, Oncology Unit, 3rd Dpt of Internal Medicine, @uoaofficial Sotiria Hospital